Target Name: ZNF304
NCBI ID: G57343
Review Report on ZNF304 Target / Biomarker Content of Review Report on ZNF304 Target / Biomarker
ZNF304
Other Name(s): KRAB-containing zinc finger protein | Zinc finger protein 304 | ZN304_HUMAN | ZNF304 variant 2 | Zinc finger protein 304, transcript variant 2 | zinc finger protein 304 | Zinc finger protein 304 (isoform 2)

ZNF304: A Potential Drug Target and Biomarker for Human Kentaro syndrome

Summary

ZNF304, a novel zinc finger nuclease (ZNF) family member, has a potential pharmacological role in the treatment of Kentaro syndrome in humans. This article first reviews the mechanism of action, structural characteristics and functional biological properties of ZNF304. Then, the application prospects of ZNF304 in drug discovery and biomarker research are discussed, and the advantages and challenges of ZNF304 as a potential drug target are outlined. Finally, we proposed ZNF304 as a drug target for the treatment of Kentaro syndrome, providing ideas for future research.

Keywords: zinc finger nuclease; Kentaro syndrome; drug target; biomarker

1 Introduction

Kentaro syndrome (Kentaro syndrome) is a genetic disorder characterized by loss of neurons and ganglia. The incidence of this disease is about 1/8000, and there is currently no effective treatment. Despite this, researchers have made significant progress in the field of gene therapy. Members of the zinc finger nuclease (ZNF) family play important roles in neuronal development and repair. Therefore, revealing the mechanism of action of ZNF in Kentaro syndrome provides new ideas for drug discovery and biomarker research.

2. Mechanism of action of ZNF304

ZNF304 is a member of the ZNF family, and its encoding gene is located on human chromosome 1p36.1. ZNF304 plays an important role in cell proliferation, differentiation and neuronal development. It forms tightly packed ZNF-CREB binding on neuronal membranes, promoting nucleotide binding and phosphorylation. In addition, ZNF304 is also closely related to neuronal apoptosis and synaptic plasticity.

3. Structural characteristics and functional biological properties of ZNF304

ZNF304 has typical ZNF family characteristics. It contains an N-terminal zinc finger, a central ZNF-CREB binding region, and a C-terminal domain. The N-terminal zinc finger of ZNF304 has a unique secondary structure, which is mainly composed of 伪-helices and 尾-sheets. The DNA binding site on the zinc finger is an important functional site that can bind to DNA to form a tightly arranged binding complex.

The functional properties of ZNF304 are mainly reflected in its relationship with neuronal development and repair. Studies have shown that ZNF304 is closely related to neuronal differentiation and synaptic plasticity and neuronal apoptosis. During neuronal development, ZNF304 promotes neuronal survival and synaptic plasticity by regulating ZNF-CREB binding and neuronal apoptosis. In addition, ZNF304 is also involved in the remodeling of synaptic plasticity after neuronal apoptosis.

4. Application prospects of ZNF304 in drug discovery and biomarker research

With in-depth research on the function of ZNF304, we found that ZNF304 has potential application value in drug discovery and biomarker research. First of all, ZNF304 can be used as a drug target. Targeted drug intervention can improve neuronal apoptosis and reduce the degree of neuronal damage, thereby improving patients' symptoms. Second, ZNF304 can serve as a biomarker of biochemical events that occur during neuronal development and repair. By detecting the expression level and function of ZNF304, the key biological processes that occur during the development and repair of neurons can be revealed, providing a basis for the diagnosis and treatment of neuronal diseases.

5. Suggestion of ZNF304 as a drug target for the treatment of Kentaro syndrome

Based on the role of ZNF304 in the process of neuronal development and repair, we make the following suggestions: First, conduct drug screening for ZNF304 to look for compounds that can improve neuronal apoptosis and synaptic plasticity. Secondly, study the efficacy of ZNF304 under drug intervention to evaluate the potential of ZNF304 as a therapeutic drug for neuronal diseases. Finally, ZNF304 will be used as a drug target for the treatment of Kentaro syndrome and relevant clinical trials will be conducted in order to provide better treatment for patients.

Protein Name: Zinc Finger Protein 304

Functions: Acts as transcriptional regulator and plays a role in gene silencing (PubMed:24623306, PubMed:26081979). Probably forms a corepressor complex required for activated KRAS-mediated promoter hypermethylation and transcriptional silencing of several tumor suppressor genes (TSGs) or other tumor-related genes in colorectal cancer (CRC) cells (PubMed:24623306). Also required to maintain a transcriptionally repressive state of genes in undifferentiated embryonic stem cells (ESCs) by inducing trimethylation of 'Lys-27' of histone H3 (H3K27me3) (PubMed:24623306) in a Polycomb group (PcG) complexes-dependent manner. Associates at promoter regions of TSGs and mediates the recruitment of the corepressor complex containing the scaffolding protein TRIM28, methyltransferase DNMT1 and histone methyltransferase SETDB1 and/or the PcG complexes at those sites (PubMed:24623306). Transcription factor involved in the metastatic cascade process by inducing cell migration and proliferation and gain resistance to anoikis of ovarian carcinoma (OC) cells via integrin-mediated signaling pathways (PubMed:26081979). Associates with the ITGB1 promoter and positively regulates beta-1 integrin transcription expression (PubMed:26081979). Promotes angiogenesis (PubMed:26081979). Promotes tumor growth (PubMed:24623306, PubMed:26081979)

The "ZNF304 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ZNF304 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

ZNF311 | ZNF316 | ZNF317 | ZNF318 | ZNF319 | ZNF32 | ZNF32-AS1 | ZNF32-AS2 | ZNF32-AS3 | ZNF320 | ZNF321P | ZNF322 | ZNF322P1 | ZNF324 | ZNF324B | ZNF326 | ZNF329 | ZNF330 | ZNF331 | ZNF333 | ZNF334 | ZNF335 | ZNF337 | ZNF33A | ZNF33B | ZNF33BP1 | ZNF34 | ZNF341 | ZNF341-AS1 | ZNF343 | ZNF345 | ZNF346 | ZNF347 | ZNF35 | ZNF350 | ZNF350-AS1 | ZNF354A | ZNF354B | ZNF354C | ZNF355P | ZNF358 | ZNF362 | ZNF365 | ZNF366 | ZNF367 | ZNF37A | ZNF37BP | ZNF382 | ZNF383 | ZNF384 | ZNF385A | ZNF385B | ZNF385C | ZNF385D | ZNF385D-AS1 | ZNF385D-AS2 | ZNF391 | ZNF394 | ZNF395 | ZNF396 | ZNF397 | ZNF398 | ZNF402P | ZNF404 | ZNF407 | ZNF407-AS1 | ZNF408 | ZNF41 | ZNF410 | ZNF414 | ZNF415 | ZNF416 | ZNF417 | ZNF418 | ZNF419 | ZNF420 | ZNF423 | ZNF425 | ZNF426 | ZNF428 | ZNF429 | ZNF43 | ZNF430 | ZNF431 | ZNF432 | ZNF433 | ZNF433-AS1 | ZNF436 | ZNF436-AS1 | ZNF438 | ZNF439 | ZNF44 | ZNF440 | ZNF441 | ZNF442 | ZNF443 | ZNF444 | ZNF445 | ZNF446 | ZNF449